Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that mast cells in Erythema Toxicum lesions in newborns are actively involved in the immune response around hair follicles, but do not express the antimicrobial peptide LL-37.

This study found that the combination of letrozole and quercetin loaded in spanlastics showed enhanced cytotoxicity and other anticancer effects against MCF-7 breast cancer cells compared to individual treatments.

This study found that women with genetic hair loss experienced significant improvements in hair density, count, and thickness when treated with both Rehmannia root extract and microneedling therapy, with the combination showing the greatest benefits compared to each treatment alone.

This study found that Carthamus tinctorius floret extract, at a concentration of 0.05 mg/mL, significantly inhibited 5α-reductase activity in DU-145 cells more effectively than standard treatments finasteride and dutasteride, with a stable microemulsion formulation enhancing its skin permeation and stability.

This case report details a probable severe adverse event associated with ritlecitinib for alopecia areata, highlighting risks of pulmonary emboli, infection, atrial fibrillation, and acute kidney injury despite an absence of known risk factors.

In this study, researchers analyzed hair follicle development in Yongqing Rex rabbits, finding dynamic changes in fur thickness, coat density, and hair structure across 1 to 6 months, along with fluctuations in follicle density and gene expression linked to hair growth and quality.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

This case series observed that 57% of pediatric patients with alopecia areata experienced significant hair regrowth with methotrexate treatment, which was generally safe, although some results were inconclusive due to follow-up issues.

This study evaluated the real-world use of ritlecitinib for severe alopecia areata in the UK, reporting that 37% of patients achieved significant hair regrowth by week 36, with no serious adverse effects noted, although response varied with disease duration.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

In this study using a mouse model with alopecia areata, the researchers found that ruxolitinib enhances hair regrowth by inhibiting the JAK-STAT signaling pathway, reducing inflammation and oxidative stress, and decreasing apoptosis, which supports its clinical effectiveness in treating this condition.

This case study found that a 9-year-old girl with trichorhinophalangeal syndrome type 1 experienced significant improvements in hair density and length after 4 months of topical minoxidil treatment, suggesting its therapeutic potential for this condition.

This case study reported significant but temporary hair regrowth and skin repigmentation in a patient with vitiligo and alopecia areata during treatment with oral ruxolitinib.

This report describes four cases of monilethrix in children and concludes that periodic inhibition of keratin synthesis, not a metabolic defect, may explain the hair abnormality.

A woman with a skin disorder was found to have hepatitis C, which may be linked, and was safely treated with methotrexate.

This study observed that in mice, small-scale x-ray irradiation resulted in uniquely rapid healing of hair follicles, differing from the hypertrophic and hyperplastic responses seen in larger irradiated areas.

This study found that subthermal CRET treatment increased keratinocyte proliferation and modulated cytokine production, affecting the inflammatory response in human keratinocytes through EGFR and ERK1/2/NF-κB pathways.

In this study, a 14-year-old girl developed Malassezia folliculitis and seborrheic dermatitis after starting trametinib, which improved with itraconazole treatment. The research underscores the importance of recognizing trametinib-related skin reactions and suggests managing them with antifungal therapy without necessarily discontinuing the medication.

This study identified a new pathogenic variant, c.1081G>T; p.(Glu361*), in the KRT31 gene as a cause of autosomal-dominant monilethrix, highlighting the role of hair keratin proteins in hair and nail tissue disorders.

This study found that deficiency in TLR3/TRIF signaling reduced inflammation and protected mice against postoperative ileus, suggesting potential for TLR3 antagonism as a preventive approach in humans.

In this study, researchers developed an optimized formulation of a traditional ethnomedicinal recipe from East Nusa Tenggara, which demonstrated strong antioxidant activity and significantly enhanced hair growth in a mouse alopecia model, compared to control groups.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

This study found that a single injection of Platelet Rich Stroma improved knee function and reduced pain and stiffness in patients with knee osteoarthritis over twelve months.